CLAIMS

Claims 1-4, 7-8, 10-15, 32-34 and 38 are currently pending in this application. Please amend Claims 1-4; 7-15; and 32 without prejudice or disclaimer of the subject matter thereof. are Currently Amended. Claims 5, 6 and 9 have been withdrawn without prejudice or disclaimer of the subject matter thereof. Claims 16-31, 35-37 and 39 were previously cancelled without prejudice or disclaimer of the subject matter thereof.

- 1. (Currently Amended) A lipid phosphatase assay method comprising the steps of: exposing a lipid detector protein containing a lipid recognition motif with a binding specificity for a product lipid of a lipid phosphatase, to a solution containing a substrate lipid of said lipid phosphatase; and determining whether said product lipid is present in said solution the presence of a lipid product of a lipid phosphatase, comprising: (a) providing a solution containing a substrate lipid of a lipid phosphatase; (b) contacting the substrate lipid of the lipid phosphatase with a lipid detector protein containing a lipid recognition motif having a binding specificity for a product lipid of the lipid phosphatase; and determining a change in concentration of at least one of the following: substrate lipid, lipid dectector protein, and lipid product, wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said product lipid is present in said solution.
- 2. (Currently Amended) The lipid phosphatase assay method according to claim 1, wherein the assay method is a direct assay or a competitive assay wherein said product lipid has a stronger affinity to said lipid detector protein than said substrate lipid.

Application No. 10/712,073 Attorney Docket No: 007262-30 US 3. (Currently Amended) The lipid phosphatase assay method according to claim 1,

wherein said lipid detector protein is an antibody against said product lipid or a lipid

recognition protein (LRP) with specificity for said product lipid.

4. (Currently Amended) The lipid phosphatase assay method according to claim 3,

wherein said lipid recognition protein contains an affinity tag fusion with PH or other lipid-

binding domains.

5. (Withdrawn) The lipid phosphatase assay method according to claim 1, wherein

said assay is a plate-based assay.

6. (Withdrawn) The lipid phosphatase assay method according to claim 5, wherein

said assay is an enzyme linked immunosorbent assay (ELISA).

7. (Currently Amended) The lipid phosphatase assay method according to claim 1,

further comprises comprising: prior to exposing contacting said lipid detector protein to the

solution, coating a substrate of an assay plate with a non-radioactively labeled substrate lipid.

8. (Currently Amended) The lipid phosphatase assay method according to claim 7,

wherein said assay plate is coated with streptavidin, glutathione or Protein A.

9. (Withdrawn) The lipid phosphatase assay method according to claim 1, wherein

said assay is an amplified luminescence proximity homogenous assay (ALPHA).

10. (Currently Amended) The lipid phosphatase assay method according to claim 1.

wherein said assay method is a fluorogenic assay.

11. (Currently Amended) The lipid phosphatase assay method according to claim 10,

wherein the assay is a fluorescence polarization (FP) assay, fluorescence resonance energy

Application No. 10/712,073

Attorney Docket No: 007262-30 US

transfer_(FRET) assay or time-resolved fluorescence resonance energy transfer_(TR-FRET) assay.

- 12. (Currently Amended) The lipid phosphatase assay method according to claim 1, wherein additional lipids are present in said solution.
- 13. (Currently Amended) The lipid phosphatase assay method according to claim 1, wherein said lipid phosphatase acts on any PIPn and is a member selected from the group consisting of SHIP1, SHIP2, PTEN, PTPRQ, SKIP, Myotubularin, MTMR2 and OCRL1.
- 14. (Currently Amended) The lipid phosphatase assay method according to claim 1, wherein said substrate lipid is PI(3,4,5)P.sub.3, PI(3,4)P.sub.2, PI(3,5)P.sub.2, PI(4,5)P.sub.2, PI(4,5)P.sub.2, PI(3,4,5)P.sub.2, PI(3,4)P.sub.2, PI(3,5)P.sub.2, PI(3,5
- 15. (Currently Amended) The method according to claim 1, wherein said product lipid is PI(3,4)P.sub.2, PI(4,5)P.sub.2, PI(3,5)P.sub.2, PI(3,4)P₂, PI(4,5)P₂, PI(3,5)P₂, PI(3)P, PI(4)P, PI(5)P, or Phosphatidyl Inositol.

16 - 31. (Cancelled)

- 32. (Currently Amended) A method for screening a disease caused alteration of a lipid phosphatase comprising the step of using the lipid phosphatase assay method of claim 1 to detect changes in the lipid phosphatase activity in bodily tissue, blood, or serum samples whereby detection of a change indicates a disease caused alteration of a lipid phosphatase.
- 33. (Original) The method of claim 32, wherein the disease is non-insulin dependant, Type II diabetes.
- 34. (Original) The method of claim 32, wherein the disease is Cowden's disease or cancer.

Application No. 10/712,073 Attorney Docket No: 007262-30 US 35 - 37. (Cancelled)

38. (Original) A method for screening a compound having an enhancing or inhibiting effect on a lipid phosphatase comprising the step of using the lipid phosphatase assay method of claim 1 to detect changes in the lipid phosphatase activity.

39. (Cancelled)